

# DEWS Report Index\*

- A**
- abbreviations, 74, 180  
accessory lacrimal glands, 185-87  
ACE (angiotensin converting enzyme) inhibitors, 82  
acne rosacea, tetracycline for, 171-72  
ACR50, ACR70, 73  
acute ocular surface inflammation, 185  
ADDE. *See* aqueous deficient dry eye (ADDE)  
affected population, 115-16  
age and aging, 78, 96  
age-related dry eye (ARDE), 73, 80  
AIDS, 80  
AKC. *See* atopic keratoconjunctivitis (AKC)  
allergic conjunctivitis, 86  
allergic eye disease, 87  
Allgrove syndrome, 80  
allogeneic bone marrow transplantation, 100  
alpha-fodrin, 186  
American Academy of Ophthalmology Preferred Practice Patterns, 163  
American Congress of Rheumatology (ACR) indices, 159  
American-European Consensus Group, 103t  
androgen  
  deficiency, 78, 83-84, 187-89  
  levels, 100  
  topically applied, 171  
androgen insensitivity syndrome, 78  
angiogenesis, tetracyclines and, 171  
animal models  
  for dry eye disease, 181-82  
  meibomian gland, 188-89  
  ocular surface, 182-83  
  tear film, 181t  
antiandrogen therapy, 78, 187-88  
anti-inflammatory therapy, 170-73  
  corticosteroids, 171  
  cyclosporine-A (CsA), 170  
  tetracyclines, 171-73  
aqueous deficient dry eye (ADDE), 76, 110  
  classification, 77f, 79  
  defined, 73, 78  
  lacrimal secretory response and, 87  
aqueous tear deficiency (ATD), 73, 85f  
ARDE, 73, 80  
artificial tears, 73, 171  
  characteristics and effects of, 164-65  
  hypo-osmotic, 166  
  ocular surface disorders and, 84  
  osmolarities of, 165  
  preservatives, 165-66  
asymptomatic dry eye disease, 110, 112  
atopic keratoconjunctivitis (AKC), 73  
at-risk population, screening, 112  
ATS. *See* artificial tear substitute  
autoantigens, 183  
autoimmune acinar damage, 79  
autoimmune disease, research, 183-85  
autologous serum, 169-70
- B**
- BAC. *See* benzalkonium chloride (BAC)  
basic science studies, 163t  
Baudoin, Christophe, 65, 71  
Baudouin, C., 86  
Beaver Dam Eye Study, 81, 86, 93, 95t  
Begley, C. B., 118, 120t  
Behrens, A., 173  
benzalkonium chloride (BAC), 165  
  ocular surface disorders and, 84  
  tear film instability and, 87-88  
Beurman, R. W., 189  
bicarbonate-containing solutions, 166  
bilateral sensory loss, 81  
biological tear substitutes, 169-70  
  saliva, 169, 170  
  serum, 169-70  
Bjerrum questionnaire, 103t  
blepharitis  
  chronic posterior, 172  
  posterior, 82-83  
blinking time, 168  
blink rate, 78, 83-84  
blood, as biological tear substitute, 169-70  
Blousse, V., 83  
Blue Mountains Eye Study, 95t, 100  
Bombardieri, S., 119t  
bone marrow transplantation, 100  
Brewitt, H., 88  
Bron, Anthony J., 66, 69, 71  
Brush Cytology Technique, 144t  
BUT. *See* fluorescein break-up time (test)
- C**
- CAE. *See* Controlled Adverse Environment  
Canadian Dry Eye Epidemiology Study (CANDEES), 102t, 104, 118t  
cancer, 100  
canine models, immune system, 184  
carboxymethyl-cellulose (CMC) solution, 166  
castor oil, 167  
cataract surgery, in patients with dry eye, 98-99  
CCLR. *See* Centre for Contact Lens Research (CCLR)  
cevimeline, 169  
challenge clinical trials, 73  
chemical burns, 81  
cholinergic agonists, 169  
chronic ocular surface inflammation, 185  
chronic posterior blepharitis, 172  
CIC. *See* Conjunctival impression cytology (CIC)  
cicatrical pemphigoid, 81  
classification, 76-88  
  aqueous tear-deficient dry eye, 78-82  
  causative mechanisms of dry eye, 86-88  
  etiopathogenic, 77-86  
  evaporative dry eye, 82-86  
  severity, 77, 89  
  symptoms, 88  
  systems, 76-77  
CLEK Schema, 73, 118, 128-29t  
clinical studies, 163t  
  clinical trials, 153-60  
    administration, 156  
    challenges in, 153  
    collaborative, 159-60  
    controlled adverse environment (CAE), 158  
    data analysis, 155-56  
    design, 153-54  
    evaluation and outcome parameters, 158  
    exclusion criteria, 154-55, 156, 158  
    goals for, 153  
    guidelines for, 153-58  
    inclusion criteria, 154-55, 156, 158  
    observations from, 158-59  
    organization of, 157t  
    outcome analysis, 155, 156, 158-59  
    peculiarities of, 158  
    placebo effects, 158, 159  
    primary outcome measures, 159  
    randomized, 74, 154, 155  
  sample size, 155, 158  
    surrogate outcome measures, 155, 159  
  collaborative clinical trials, 159-60  
  colloidal osmolarity, 166  
  Complete Androgen Insensitivity Syndrome, 187-88  
  computer use, 100  
  computer vision syndrome (CVS), 73, 100  
  congenital alacrima, 80  
  Congress of the European Society of Ophthalmology, 77  
  conjunctiva, 118, 184t  
  Contact Lens Dry Eye Questionnaire (CLDERQ), 84, 103t  
  contact lenses  
    corneal sensitivity and, 81  
    dry eye and, 84-86, 98, 100-101  
    hydrogel, 84  
    intolerance, 84  
    protection of corneal surface by, 168  
    soft, 85  
    tear film and, 84, 88  
    visual performance and, 85-86  
  controlled adverse environment (CAE), 73, 121, 158  
  corneal surface  
    contact lenses and, 168  
    fluorescein staining, 118, 171  
    irregularity, 98  
    sensitivity, 87  
  correlative surrogate markers, 159  
  corticosteroids, 171  
  CPT, 73, 96  
  Craig, J. P., 80  
  cranial nerve VII, 82  
  crossover design trials, 154  
  crystalloid osmolarity, 166  
  Cuckle, H., 115  
  Cullen Symposium on Corneal & Ocular Surface Inflammation, 185  
  current procedure terminology (CPT), 73, 96  
  cut-off values, 115, 117, 119  
  CVS. *See* computer vision syndrome (CVS)  
  cyclosporine-A (CsA), 170, 184
- D**
- Damato, B. E., 80  
data analysis, for clinical trials, 155-56  
"Definition and Classification of Dry Eye Disease, The" (Definition and Classification Subcommittee), 75-89  
Definition and Classification Subcommittee, 75-89, 110  
goals, 75  
Delphi group, 111  
Delphi Panel, 76, 77  
demographics, clinical trials and, 154  
De Paiva, C. S., 101  
depression, in Sjogren syndrome (SS), 98  
DEQ. *See* Dry Eye Questionnaire (DEQ)  
DES. *See* dry eye syndrome (DES)  
Detection Rate (DR), 114, 115  
DEWS report  
  authorship, 70  
  glossary, 73-74  
  Introduction, 69-70  
DEWS Research Committee Report Form, 179  
diabetes mellitus, 81-82

\*Index compiled by Marilyn Rowland.

f = figure; t = table

- diagnosis, 108-22. *See also* diagnostic tests  
 criteria for, 108  
 differential, 111  
 Japanese criteria for, 127t  
 overdiagnosis, 119-20  
 recommendations for, 121-22
- Diagnostic Methodology Subcommittee, 108  
 goals of, 109
- diagnostic tests, 111-22  
 affected population, 115-16  
 appraisal of, 112, 115-16  
 characteristics, 114-15t  
 combined, 119  
 cut-off values, 115, 117, 119  
 efficacy of, 112, 114  
 emerging technologies, 120  
 false positives, 115-16  
 likelihood ratio (LR), 115  
 limitations of, 112  
 listing, 108  
 Odds of being Affected in those with a  
 Positive test Result (OAPR), 115-16  
 protocol for evaluating, 116-17  
 recommendations for, 117-22  
 screening tests, 112-15  
 selection bias, 112  
 sequence of, 117t  
 spectrum bias, 112  
 templates, 109-10, 126, 128-52  
 true positives, 115-16  
 unaffected population, 115-16  
 uses of, 111  
 web videos, 110
- diglycerides, in tear film, 83
- diquafosol, 168-69
- direct surrogate markers, 159
- disodium (EDTA), 165
- Dogru, M., 120t
- Dougherty, J. M., 171
- dry eye disease  
 animal models, 181-82  
 asymptomatic, 110  
 basis for symptoms, 88  
 bone marrow transplantation and, 100  
 burden of, 97-98  
 causative mechanisms of, 86-88  
 causes of, 78  
 challenges of, 69  
 classification of, 75, 76-89  
 computer use and, 100  
 contact lenses and, 98, 100-101  
 defined, 75-76, 78, 93-94, 110  
 Delphi Panel, 76, 77  
 diagnosis, 108-22  
 diagnostic tests, 111-22  
 environmental influences, 78  
 essential fatty acids and, 100  
 etiological causes of, 77f  
 financial costs of, 97  
 incidence of, 96  
 low humidity environments and, 100  
 magnitude of prevalence, 96-97  
 management and therapy, 163-74  
 mechanisms of, 85f, 180  
 menopausal hormonal therapy and, 100  
 misclassification of, 76  
 monitoring, 122  
 morbidity of, 97  
 natural history of, 96  
 NEI/Industry Workshop classification, 76  
 ocular morbidity and, 98-99  
 ocular symptoms, 110  
 prevalence, 93, 95-96  
 quality of life and, 97  
 recommended research in, 99  
 refractive surgery and, 101  
 regional prevalence, 96  
 research, 179-89  
 risk factors, 96, 99-100, 99t  
 severity, 111, 112, 173t  
 severity grading, 88t, 89  
 sex hormones and, 100  
 symptomatic ocular surface disease (SOSD)  
 and, 111  
 symptoms, 75, 94, 110  
 treatment, 173-74, 174t  
 Triple Classification, 76-77  
 underreporting, 96-97  
 vicious circle of, 78, 85f  
 visual function impacts, 98
- Dry Eye Epidemiology Project (DEEP), 102t  
 questionnaire, 104
- dry eye overdiagnosis, 119-20
- Dry Eye Preferred Practice Patterns of the  
 American Academy of Ophthalmology, 173-74
- Dry Eye Questionnaire (DEQ), 73, 102t, 118, 118t
- Dry Eye Questionnaire (DEQ) and Contact Lens  
 DEQ, 105
- dry eye questionnaires. *See* questionnaires
- dry eye syndrome (DES), 73
- dry eye therapies  
 anti-inflammatory therapy, 170-73  
 assessment of, 164-73  
 biological tear substitutes, 169-70  
 environmental strategies, 173  
 essential fatty acids, 173  
 lubricants, 164-67  
 recommendations, 173-74  
 salivary gland autotransplantation, 170  
 tear retention, 167-68  
 tear stimulation, 168-69  
 tear supplementation, 164-67
- Dry Eye WorkShop (DEWS), 65
- Dupin-Spriet, T., 157f
- dysfunctional tear syndrome, 73, 77, 111
- 
- E**
- ecabet sodium, 169
- ECP. *See* eosinophil cationic protein (ECP)
- EDE. *See* evaporative dry eye (EDE)
- EDTA, 165
- Efron, N., 84
- electrolyte composition, of tear  
 supplementation, 166
- Ellwein, L. B., 96
- environmental clinical trials, 73, 156
- environmental influences, 78
- environmental strategies, 173
- eosinophil cationic protein (ECP), 73
- epidemiology  
 challenges in, 94-95  
 defined, 93  
 population-based studies, 95t  
 "Epidemiology of Dry Eye Disease"  
 (Epidemiology Subcommittee), 93-106  
 Epidemiology Subcommittee, 93  
 epithelial damage, 85f, 166, 185, 189  
 Epstein-Barr virus infection, 185
- Erdelyi, B., 120t
- Erickson, Susan, 66
- erythema multiforme, 81
- Esquivel, E., 166
- essential fatty acids, 100, 173  
 estrogen, 78
- estrogen therapy, 78, 171
- Ethis Communications, 66
- evaporative dry eye (EDE), 76, 82-86, 110, 180  
 classification, 77f  
 defined, 73, 78  
 extrinsic causes of, 82  
 intrinsic causes of, 82-83  
 lacrimal gland insufficiency and, 87  
 lacrimal secretory response and, 87  
 evaporative water loss, 78  
 exclusion criteria, for clinical trials, 154-55, 156, 158  
 "expectation of randomization," 158
- Eye Care Technology Forum Impacting Eye  
 Care, The, 103t
- eye drops, 84
- eye masks, 168
- 
- F**
- false-negative results, 112
- False-Positive Rate (FPR), 114, 115
- false positives, 115-16
- familial dysautonomia (Riley Day syndrome), 80
- fatigue, in Sjogren syndrome (SS), 98
- fatty acids, 83
- Ferning Test (TFT), 147-48t
- Flow cytometry in impression cytology, 145-46t
- fluorescein staining, 118, 171
- fluorometholone, 171
- Fluorophotometry (Fluorimetry)—Tear Flow  
 test, 150-51t
- Foulks, Gary N., 65-66, 70, 71
- Freeman, J. M., 167
- Freeman style punctal plugs, 167, 168
- Fujishima, H., 86
- 
- G**
- galyfilcon contact lenses, 88
- gefarnate, 169
- gene expression, in accessory glands, 186
- Giles, I., 98
- Gipson, I. K., 71, 189
- Glasson, M. J., 84
- glaucoma, ocular surface disorders and, 84
- glossary, 73-74
- glycan array methodologies, 180
- goblet cell density, 88
- goblet cell loss, 78  
 tear hyperosmolarity and, 86  
 vitamin A deficiency and, 84
- goblet cells, 73
- Godaert, G. L., 98
- Goebbels, M., 82
- Goto, T., 87
- Grading Staining: CLEK Schema, 128-29t
- Grading Staining: Oxford Schema, 130-32t
- graft vs. host disease (GVHD), 73, 80, 183
- Grus, F. H., 120t
- 
- H**
- Hamill, J. R., 118
- Herrick punctal plugs, 167
- 15(S)-HETE, 169
- HLA-DR, 88
- Holly, E., 166
- Hospital Anxiety and Depression Scale (HADS), 98
- HP-guar, 167
- humidity, 100
- hyaluronic acid, 167
- hydrogel lenses, 84
- hydroxymethylcellulose (HMC), 166, 167
- hydroxypropyl-guar (HP-guar), 167

hyperosmolarity, 86-87, 122  
 hypoosmolarity, of salivary glands, 170  
 hypo-osmotic artificial tears, 166

**I**

ICAM-1, 73, 88  
 ICDM-9-CM codes, 73, 96  
 immune system  
   information matrix, 184t  
   research, 183-85  
 Impact of Dry Eye on Everyday Life (IDEEL), 73, 97, 102t, 103, 118t  
   features, 104  
 incidence, 73, 96  
 inclusion criteria, for clinical trials, 154-55, 156, 158  
 inflammation  
   anti-inflammatory therapy for, 170-73  
   information matrix, 184t  
   mechanism of, 185f  
   research, 185  
 inflammatory cytokines, 180  
 inflammatory lacrimal damage, 85f  
 inflammatory markers, 88  
 inflammatory mediators, 78  
 "intention-to-treat" principle, 155  
 interblink intervals, 168  
 International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9 CM), 96  
 International Dry Eye WorkShop (DEWS)  
   abbreviations, 74  
   defined, 73  
   glossary, 73-74  
   membership, 70  
   Report Introduction, 69-70  
   subcommittee members, 70  
   subcommittees, 69  
 International Sjogren's Classification, 118t  
 International Task Force (ITF), 173-74  
 in vitro models, 182-83  
 Isenberg, D., 98  
 Ishida, R., 120t  
 isotretinoin, 83

**J**

Japanese criteria for diagnosis, 127t  
 Japanese dry eye awareness study, 103t  
 Johnson, R., 119t

**K**

keratoconjunctivitis sicca (KCS), 73, 78, 180  
 Knop, E., 88  
 Kojima, T., 120t  
 Korb, D. R., 120t, 168  
 Kurihashi, K., 168

**L**

lacrimal acinar damage, 84  
 Lacrimal Functional Unit (LFU), 65, 189  
 damage to, 76  
 defined, 73  
 disturbance of, 76  
 lacrimal gland, 76  
   ablation, 81  
   denervation, 81  
   duct obstruction, 81  
   excessive reflex stimulation of, 87  
   hyosecretion, 79  
   infiltration, 78, 80  
   information matrix, 184t, 186t, 187t  
   insufficiency, 86-87

primary deficiencies, 80  
 reflex stimulation of, 86  
 research, 185-87  
 secondary deficiencies, 80-81  
 lacrimal secretory compensation, 87  
 lacrimal secretory response, 87  
 lacrimal tear deficiency. *See* aqueous deficient dry eye (ADDE)  
 lacrimal tear secretion  
   drug-related reduction of, 78  
   failure of, 78  
 lanolin, 165-66  
 laser assisted in situ keratomileusis (LASIK)  
   surgery. *See* LASIK surgery  
 LASIK-Induced NeuroEpitheliopathy (LINE), 73, 101  
 LASIK surgery  
   defined, 73  
   dry eye following, 81, 101  
   post-LASIK symptomatic keratitis, 111  
   tear film instability and, 87  
 last observation carried forward (LOCF), 73, 156  
 Lemp, M. A., 69, 71, 118  
 lid oil, 78-79, 85f  
 lids, 76  
   aperture disorders, 83  
   commensal organisms, 83  
   lid/globe congruity, 83  
 likelihood ratio (LR)  
   for diagnostic tests, 115  
 lipids, 181t, 188t  
 lissamine green staining, 118  
 Liu, H., 120t  
 low-humidity environments, 100  
 low-income populations, 96-97  
 lubricants  
   characteristics and effects of, 164-67  
   electrolyte composition, 166  
   osmolarity, 166  
   preservatives, 165-66  
   viscosity agents, 166-67  
 lymphoma, 80

**M**

macromolecular complexes, 166  
 Magalhaes, M., 84  
 Management and Therapy Subcommittee, 163  
   goals, 163  
 Maruyama, K., 168  
 mass spectrometry, 180  
 Mathers, W. D., 80, 120t  
 McCarty, C., 118  
 McCulley, J. P., 83  
 McMonnies Dry Eye Questionnaire, 84, 102t, 118t  
   features, 104  
 Medical Outcome Study Short Form-36, 97  
 meibography, 83, 143t  
 meibometry, 83, 142t  
 meibomian excreta (meibum), 121  
 meibomian foam, 83  
 meibomian gland, 121  
   animal models, 188-89  
   atrophy, 83  
   information matrix, 188t, 189t  
   lipids, 180  
   obstruction, 82-83  
   research, 187-89  
 meibomian gland dysfunction (MGD), 82-83, 85f, 111, 121, 172, 188  
   allergic conjunctivitis and, 86  
   amount of oil in lid margin reservoir, 83  
   causing evaporative dry eye, 82t

cicatricial, 83  
 degree of, 83  
 degree of gland dropout, 83  
 simple, 83  
 tear hyperosmolarity and, 87  
 meibomianitis, 172  
 meibomian lipids, 121, 180  
 meiboscopy, 143t  
 Melbourne Visual Impairment Project  
   Questionnaire, 93, 95t, 103t, 105  
 membrane-spanning mucins, 166  
 menopausal hormone therapy (MHT), 73, 100  
 Mertzanis, P., 97  
 methylprednisolone, 171  
 MGD. *See* meibomian gland dysfunction (MGD)  
 milieu exterieur, 77f, 78  
 milieu interieur, 77f, 78  
 mineral oil, 167  
 minority populations, 96-97  
 MMP-9 protein, 171  
 moisture chamber spectacles, 168  
 monoglycerides, 83  
 morbidity, 97  
 motor nerves, 76  
 mouse models  
   dry eye disease, 181  
   immune system, 184  
   lacrimal gland, 186  
   ocular surface, 183  
 MUC-4, 73, 166  
 MUC-16, 166  
 MUC5AC, 88, 180  
 mucin markers, 88  
 mucins, 73, 166, 180, 181t, 182t  
 mucous membrane pemphigoid, 81  
 multi-dimensional fatigue inventory (MFI), 73, 98  
 multidose artificial tears, 165  
 multifactorial diseases, 159  
 multinational clinical trials, 159-60  
 muscarinic receptors, 186

**N**

nasolacrimal duct  
   information matrix, 186t, 187t  
   research, 185-87  
 National Eye Institute (NEI), 69, 75, 93  
 National Eye Institute (NEI) 42-Item Refractive Error Questionnaire, 103t  
 National Eye Institute (NEI)/Industry Workshop classification, 76  
 National Eye Institute (NEI)-Visual Function Questionnaire (NEI-VFQ), 74, 97, 98, 102t, 104-5  
 Nemeth, J., 120t  
 nervus intermedius, 82  
 neurogenic inflammatory cytokine response, 87  
 neurotrophic keratitis, 82  
 neurturin-deficient mice, 181  
 Nichols, J. J., 86, 168  
 Noda-Tsuruya, T., 170  
 "non-autoimmune" dry eye, 78  
 non-invasive TFBUT, 121, 122  
 non-Sjogren syndrome dry eye (NSSDE), 180  
   age-related, 80  
   classification, 77f  
   defined, 74, 80  
   forms of, 80, 80t  
   IDEEL questionnaire and, 97  
   lacrimal gland duct obstruction, 81  
   lid oil and, 78-79  
   primary lacrimal gland deficiencies, 80  
   reflex hyosecretion, 81-82  
   secondary lacrimal gland deficiencies, 80-81

"normal-cholesterol absent" group (N[CA]), 83  
 "normal-cholesterol present" group (N[CP]), 83  
 nutritional deficiencies, 79

**O**

ocular allergy, 86  
 ocular comfort  
   moisture chamber spectacles and, 168  
   tear supplementation and, 164  
 ocular irritation, 76  
 ocular lubricants. *See* lubricants  
 ocular morbidity, 98-99  
 ocular ointments and gels, 165-66  
 Ocular Protection Index (OPI), 87, 149t  
 ocular sensory loss, 81t  
 ocular surface, 76  
   animal models, 182-83  
   chronic inflammation, 185  
   disorders, 84  
   dryness, 79t, 119  
   epithelial cell hyperosmolarity, 78  
   hyperosmolarity, 85f  
   inflammation, 76, 168, 185  
   information matrix, 182t, 183t  
   protection of, 166  
   research, 182-83, 182t  
   staining, 118  
 ocular surface disease, 86  
   classification, 110-11, 111f  
   research, 183  
 Ocular Surface Disease Index (OSDI), 97, 102t, 118t  
   defined, 74  
   features, 104  
 ocular surface system (OSS), 74, 189  
 ocular symptoms, 110  
 Odds of being Affected in those with a Positive  
   test Result (OAPR)  
   calculating, 116  
   for diagnostic tests, 114, 115-16  
   prevalence and, 116f  
 oncotic pressure, 166  
 optical aberrations, 98  
 osmolarity  
   colloidal, 166  
   crystalloid, 166  
   of tear supplementation, 166  
 osmoprotection, 166  
 Ousler, G. W., 120t  
 outcome analysis, for clinical trials, 155, 156, 158-59  
 overdiagnosis, 119-20  
 Oxford Schema, 118, 130-32t

**P**

palpebral aperture  
   natural height of, 78  
   width of, 78  
 parallel group studies, 154  
 Parkinson disease (PD), 83  
 Pflugfelder, S. C., 71, 119, 189  
 PharMetrics' Integrated Outcomes, 96  
 photorefractive keratoplasty (PRK), 74, 101  
 Physicians' Health Study (PHS), 74, 93, 95, 95t  
 pilocarpine, 169  
 Pisella, P. J., 88  
 placebo effects, 74, 158, 159  
 polychlorinated biphenyls, 83  
 polymacon contact lenses, 88  
 posterior blepharitis, 82-83  
 post-LASIK symptomatic keratitis, 111  
 potassium, 166  
 predictive value of a positive test (PPV), 114

pre-lens tear film (PLTF), 84  
 preservatives  
   elimination of, 165-66  
   ocular surface disorders and, 84  
   tear film instability and, 87-88  
   in tear supplements, 165-66  
   "vanishing," 165  
 prevalence, 93, 95-97  
   defined, 74  
   magnitude of, 96-97  
   Odds of being Affected in those with a  
     Positive test Result (OAPR) and, 116f  
   regional, 96  
   underreporting, 96-97  
   in women, 84, 95  
 Prichard, N., 100-101  
 primary lacrimal disease, 80  
 primary lacrimal gland deficiencies, 80  
 primary outcome measures, 155, 159  
 primary Sjogren syndrome, 79  
 proteins, 181t  
 punctal occlusion, 167-68, 171, 186  
 punctal plugs  
   absorbable, 167  
   clinical studies, 167-68  
   complications, 168  
   contraindications for, 168  
   Freeman style, 167, 168  
   Herrick, 167  
   indications for, 168  
   nonabsorbable, 167  
   Smartplug, 167  
   tear production and, 168  
 punctate keratoconjunctivitis, 86

**Q**

quality of life (QoL)  
   defined, 74  
   in dry eye disease, 97  
   in Sjogren syndrome, 98  
   tear supplementation and, 164  
 questionnaires  
   characteristics, 113  
   in current use, 118  
   evaluation, 105  
   features of, 104-5  
   recommendations for, 117-18  
   research needed, 105  
   review of, 101-5  
   symptoms and quality of life instruments, 102-3t

**R**

rabbit models  
   androgen deficiency, 188-89  
   lacrimal gland, 181, 187t  
 Rajagopalan, K., 120t  
 randomized clinical trials, 74, 154, 155  
 rebamipide, 169  
 receiver-operator characteristic (ROC) curve, 117  
 reflex hyposecretion, 81-82  
 reflex sensory block, 81  
 reflex tearing, 76, 118-19, 120-21  
 reflex trigeminal activity, 86  
 refractive surgery, 101. *See also* LASIK surgery  
 research, 179-89  
   accessory lacrimal glands, 185-87  
   dry eye mechanisms, 189  
   immune system, 183-85  
   inflammation, 185  
   lacrimal gland, 185-87  
   meibomian gland, 187-89  
   nasolacrimal duct, 185-87

ocular surface, 182-83  
   tear film, 179-82  
 Research Subcommittee, 65, 179  
   goals of, 179  
 Riley Day syndrome, 80  
 rose bengal staining, 167

**S**

S. aureus, 83  
 Salisbury Eye Evaluation Questionnaire, 93, 102t  
   features, 104  
 Salisbury Eye Study, 95t  
 saliva, as tear substitute, 169, 170  
 salivary gland autotransplantation, 170  
 sample size, for clinical trials, 155, 158  
 sarcoidosis, 80  
 Schein, O. D., 82, 118, 120t  
 Schein questionnaire, 118t  
 Schiffman, R. M., 120t  
 Schirmer test, 118-19, 126-27t  
   defined, 74  
   without anesthesia, 74, 135t  
 screening tests  
   appraisal of, 112-15  
   defined, 112  
   recommendations for, 117-21, 119-20  
 seasonal allergic conjunctivitis, 87  
 secondary lacrimal gland deficiencies, 80-81  
 secondary Sjogren syndrome, 79  
 secretagogues, 74, 168-69  
 selection bias, in diagnostic tests, 112  
 sensitivity, of diagnostic tests, 74, 114  
 sensory nerves, 76  
 serum, as tear substitute, 169-70  
 severity grading, 77, 89  
 sex hormones, 78, 100  
 sex steroid deficiency, 100  
 Shack-Hartmann aberrometer, 98  
 Shihpai study, 95t, 100  
 Shimazaki, J., 87  
 Shine, W. E., 83, 171  
 Sicca/SLE Questionnaire, 103t  
 Sicca/SS Questionnaire, 103t  
 silicone hydrogel contact lenses, 88  
 single unit-dose tear substitutes, 165  
 Sjogren syndrome (SS), 111  
   classification, 76, 77f, 79f  
   criteria for ocular manifestations of, 119t  
   quality of life in, 98  
 Sjogren syndrome dry eye (SSDE), 79-80, 180  
   autoantibodies, 79t  
   defined, 79  
   forms of, 79  
   histopathology, 79t  
   nutritional deficiencies and, 79  
   ocular dryness, 79  
   ocular signs, 79t  
   ocular symptoms, 79t  
   oral syndromes, 79t  
   primary, 79  
   salivary gland involvement, 79t  
   secondary, 79  
 Sjogren syndrome-related KCS  
   IDEEL questionnaire and, 97  
   tear stimulation and, 169  
 Smartplug, 167  
 Smith, J., 71, 118  
 sodium chlorite, 165  
 sodium borate, 165  
 soft contact lenses, 85  
 specificity, in diagnostic tests, 74, 114-15  
 spectrum bias, in diagnostic tests, 112

Spriet, A., 157f  
 Standards of Good Clinical Practice, 156  
 staring tear breakup dynamics (S-TBUD), 121  
 Stern, J. J., 173  
 Stern, M. E., 189  
 Stevenson, H. A., 98  
 Strombeck, B., 98  
 Sullivan, Amy G., 65, 70  
 Sullivan, B., 120t  
 Sullivan, David A., 65, 69, 70, 71  
 Sullivan, Rose M., 65, 70  
 Sumatra study, 95t  
 surrogate markers, 74, 155, 159  
*Survey Manual and Interpretation Guide*, 97  
 Sutcliffe, N., 98  
 symptomatic conjunctivitis, 110  
 symptomatic dry eye, 110  
 symptomatic keratitis, 110  
 symptomatic lid disease, 110  
 symptomatic ocular surface disease (SOSD)  
   classification of, 110-11  
   defined, 111  
   dry eye disease and, 111  
 symptomatology, 110  
 symptom questionnaires, 94  
 systemic drug use, 82

**T**

Tamer, C., 83  
 tear clearance rate (TCR), 74  
 tear-deficient dry eye. *See* aqueous deficient dry eye (ADDE)  
 tear film  
   animal, 181t  
   contact lenses and, 84  
   destabilization of, 76  
   hyperosmolarity, 78, 85f, 86-87  
   information matrix, 181t  
   Lacrimal Functional Unit and, 76  
   model, 166  
   noninvasive study techniques, 121, 122  
   osmolarity, 119, 122, 166, 179-80, 181t  
   research, 179-82, 182  
   thinning rates, 86  
 tear film analysis system (TMS), 87  
 tear film breakup time (TFBUT), 74, 116, 118, 133-34t  
   blink rate and, 83  
   optical aberrations and, 98  
   tear film instability and, 87  
 tear film instability, 85f, 86, 87-88  
   allergic conjunctivitis and, 86  
   LASIK surgery and, 87

tear film lipid layer interferometry, 139-40t  
 Tear Film & Ocular Surface Society, The (TFOS), 65, 69  
   officers and staff, 70  
   website, 70  
 tear film stability  
   test performance, 118  
   threats to, 76  
   viscosity agents and, 166  
 Tear Function Index (Liverpool modification), 152t  
 tear function index (TFI), 122  
 Tear meniscus radius, height, and cross sectional area, 137-38t  
 Tear Osmolarity test, 136t  
 tear retention, 167-68  
   moisture chamber spectacles, 168  
   punctual occlusion, 167-68  
 tears  
   composition, 120-21, 180  
   deficiency, 94  
   evaporation rate, 87  
   flow obstruction, 85f  
   flow reduction, 87  
   sampling, 120  
   stimulation, 168-69  
   volume, 181t  
 tear stability analysis system (TSAS), 111, 141t  
 tear supplementation  
   characteristics and effects of, 164-67  
   electrolyte composition, 166  
   osmolarity, 166  
   preservatives in, 165-66  
   viscosity agents, 166-67  
 tear turnover rate (TTR), 120  
 templates, 179  
   development of, 109-10  
   headings, 110  
   "web video" section, 110  
 testosterone, topically applied, 171  
 tetracyclines, 171-73  
   for acne rosacea, 171-72  
   anti-angiogenic properties, 171  
   antibacterial properties, 171  
   anti-inflammatory properties, 171  
   for chronic posterior blepharitis, 172  
   clinical applications, 171-73  
   dosage and safety, 172-73  
   for meibomian gland dysfunction (MGB), 172  
 Thai, L. C., 84  
 thermal burns, 81  
 Thomas, E., 98  
 Tomlinson, A., 71, 80  
 topic anesthesia, 84

trachoma, 81  
 treatment assignments, for clinical trials, 155  
 triple A syndrome (Allgrove syndrome), 80  
 Triple Classification, 76-77  
 true positives, 115-16  
 Tsubota, K., 69, 71, 168, 169

**U**

unaffected population, 115-16  
 upgaze, 78  
 U.S. Food and Drug Administration (FDA), 164, 165  
 Utility assessment questionnaire, 103t

**V**

Valtysdottir, S. T., 98  
 van Bijsterveld study, 118, 119  
 "vanishing" preservatives, 165  
 vernal keratoconjunctivitis, 74, 87  
 video display terminals, 78, 100  
 viscosity agents, 166-67  
 Vision-Targeted Health-Related Quality of Life (VT-HRQ), 74, 98  
 visual function  
   contact lenses and, 85-86  
   dry eye and, 98  
   vision, 167  
 Vitale, S., 98  
 Vitali, C., 76, 119t  
 vitamin A deficiency, 84, 87

**W**

waking tear flow, 76  
 Wald, N. J., 115  
 Wang, J., 120t  
 web videos, 110  
 women  
   dry eye prevalence, 84, 95, 100  
   dry eye risk factors, 96  
   menopausal hormone therapy (MHT), 100  
 Women's Health Study, 74, 93, 95, 95t  
 questionnaire, 102t, 104, 118t

**X**

xerophthalmia, 74, 84, 87

**Y**

Yazdani, C., 96  
 yellow barrier filers, 118  
 Yen, M. T., 186  
 Yokoi, N., 120t  
 Yoo, S. E., 172